LungLB® Test
Evaluation of indeterminate lung nodules for lung cancer risk
Commercial (LDT)Active
Key Facts
Indication
Evaluation of indeterminate lung nodules for lung cancer risk
Phase
Commercial (LDT)
Status
Active
Company
About LungLife AI
LungLife AI is a developer of clinical diagnostic solutions targeting the early detection of lung cancer, the world's deadliest cancer. Its flagship product, the LungLB® test, uses a simple blood draw and AI analysis to help clinicians manage patients with indeterminate lung nodules, aiming to improve outcomes through earlier intervention. The company operates a CLIA lab and appears to be in the commercial or late-stage validation phase for its diagnostic. Leadership combines deep expertise in translational lung cancer research, liquid biopsy technology, and financial management.
View full company profile